Tag Archives: Sandborn

Two-Drug Combo Doubles Crohn’s Disease Remission

April 8th, 2010 - 9:33 am

A study led by Mayo Clinic suggests remission from Crohn’s disease may be more likely if patients get biologic therapy, combined with immune-suppressing drugs first, instead of immune-suppressing drugs alone. The study, published in the April 15, 2010, issue of … Continue reading →

By Amy Tieder | Posted in Gastroenterology, Research | Tagged , , , , , | Comments (3)

Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half

September 25th, 2009 - 12:02 pm

A new study led by Mayo Clinic researchers has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab, according to a study published in the October 2009 issue of Gastroenterology. … Continue reading →

By Amy Tieder | Posted in Gastroenterology, Research | Tagged , , , | Comments (2)

Crohn’s Disease Patients Benefit From Infliximab Plus Azathioprine

May 27th, 2009 - 2:29 pm

The use of infliximab (IFX) plus azathioprine (AZA) and infliximab monotherapy increase the likelihood of patients achieving long-term steroid-free clinical remission in patients with moderate to severe Crohn’s disease, according to a new study. This study represents the first time … Continue reading →

By Amy Tieder | Posted in Gastroenterology, Research | Tagged , , , , , | Leave a comment